|

Interleukin-2 Clinical Trials

24 actively recruiting trials across 5 locations

No change since May 2026

Also known as: Aldesleukin, Aldesleukin, Proleukin, Aldesleukin, Proleukin, IL-2, IL-2, Proleukin +2 more

Pipeline

Early 1: 1Phase 1: 7Phase 2: 5Phase 1/2: 11

Top Sponsors

  • Essen Biotech5
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University4
  • Dana-Farber Cancer Institute3
  • H. Lee Moffitt Cancer Center and Research Institute2
  • Vall d'Hebron Institute of Oncology1

Indications

Other14 trials

A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC
Phase 1/2
A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.
Phase 2
Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study
Phase 2
Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors
Early 1
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
Phase 1/2
Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors
Phase 1
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Phase 1
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Phase 1
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Phase 1/2
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Phase 1/2
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
Phase 1/2
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
Phase 1/2
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
Phase 1/2
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
Phase 1/2

Boston, Massachusetts4 trials

CIML NK Cells With Venetoclax for AML

Brigham and Women's Hospital

Phase 1
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Brigham and Women's Hospital

Phase 1
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Dana-Farber Cancer Institute

Phase 1
TIL Therapy in cSCC and MCC

Dana-Farber Cancer Institute

Phase 2

Tampa, Florida2 trials

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

Moffitt Cancer Center

Phase 1/2
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Moffitt Cancer Center

Phase 2

Houston, Texas2 trials

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

MD Anderson Cancer Center

Phase 1/2
Phase II Clinical Trial of Interleukin-2 in AD

Houston Methodist Research Institute

Phase 2

Los Angeles, California1 trial

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Valkyrie Clinical Trials

Phase 1/2

Pittsburgh, Pennsylvania1 trial

Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease

AHN West Penn Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.